Background and objectives: Polycystic ovarian syndrome (PCOS) involves dysfunction in the endocrinal, metabolic and reproductive profile among females. D-chiro inositol is a novel treatment agent for improving the endocrinal profile seen in it. The current study aims to evaluate the effect of D-Chiro Inositol in lowering down the androgens levels in patients with PCOS.
Methodology of the study: This randomized trial was carried out at the outpatient of Department of medical sciences during June 2020 to March 2021. 50 females with polycystic ovarian disease were divided randomly into two groups, each of 25 females. One group was give D-Chiro Inositol (600mg/day) and the other was given placebo. Androgens levels i.e. LH, FSH and testosterone were assessed at baseline and then after 8 weeks. Treatment effects were compared after 8 weeks by independent sample T test and a P value of ≤0.05 was considered significant.
Results: The mean age of the patients in the treatment (D-Chiro Inositol) group was 28±8 year’s vs 30±9 years in placebo group. The mean BMI of females in D-Chiro Inositol group was 25.7±3.6 kg/m2 compared to 25.8±4.2 kg/m2 in the placebo group. The mean levels of LH, FSH and testosterone were 14.74 mIU/ml, 10.19 mIU/ml and 78.48 ng/dL in D-Chiro Inositol group vs 17.22 mIU/ml, 13.03 mIU/ml and 86.08 g/dl in placebo group. Significant difference was present between both treatment groups (P value ≤0.05).
Conclusion: D-Chiro Inositol is a promising drug for the lowering down the androgens levels in polycystic ovarian syndrome.